Study of AZD2811 + Durvalumab in ES-SCLC

Inclusion Criteria:

1. Documented evidence of extensive stage SCLC (ES-SCLC)
2. Participants must be considered suitable to receive an induction platinum-based chemotherapy regimen, combined with durvalumab, as first-line treatment for ES-SCLC
3. No prior exposure to immune-mediated therapy
4. Life expectancy ≥12 weeks at Day 1.
5. ECOG 0 or 1 at enrolment.

Exclusion Criteria:

1. Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy
2. Has a paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic treatment (systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of PNS
3. Active infection including tuberculosis, HIV, hepatitis B and C
4. Active or prior documented autoimmune or inflammatory disorders
5. Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.